DRG Market Assessment 보고서

Chronic heart failure (CHF) describes the long-term management of heart failure outside the hospital setting. CHF patients are subject to high rates of mortality and morbidity. Frequent…

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with…

Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud…

The treatment paradigm for second- and subsequent-line advanced or metastatic colorectal cancer revolves around targeted agents (such as Erbitux, Vectibix, and Avastin) with or without…

Treatment of borderline personality disorder is multimodal, involving psychotherapy and prescription pharmacotherapy. Prescription drug treatment involves an array of drug classes, including, but…

Thesystemic lupus erythematosus (SLE)therapy market in the five major pharmaceutical markets in Europe (EU5) is mostly served by off-label therapies.Benlysta is the only drug approved for SLE in…

Conventional agents (e.g., immunosuppressants, 5-ASAs) have long been used to treat pediatric Crohn’s disease (CD). Among the TNF-α inhibitors, Janssen/Merck’s Remicade and AbbVie/Eisai’s…

Acute kidney injury (AKI) is defined as functional or structural abnormalities of the kidneys that cause sudden impairment of fluid homeostasis, resulting in retention of metabolic products over a…

Pediatric attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Despite a number of available—and largely…

The opioid addiction market is dominated by opioid receptor agonist therapies for the maintenance treatment of opioid addiction, most notably generic methadone and Indivior’s Suboxone Film. The…

Friedreich’s ataxia (FA) is a progressive, autosomal recessive, neurodegenerative disease characterized by slowly advancing ataxia (loss of bodily control). No treatments are currently approved…

Introduction: The crowded U.S. rheumatoid arthritis (RA) market boasts nine different biologics representing five distinct drug classes, including the blockbuster tumor necrosis factor-alpha (…